Enterome - Model Sibofimloc/TAK-018 - First-In-Class, Orally Administered Small Molecule
Sibofimloc is a first-in-class, orally administered small molecule that is specifically designed to reduce the inflammatory cascade underlying Crohn’s disease and remain gut-restricted, to minimize absorption into the bloodstream.
It is designed to reduce inflammation by preventing:
- FimH-expressing bacteria from adhering to the gut wall,
- Activation of innate immune receptors,
- Induction of gut permeability, and
- Ultimately, inhibiting bacterial translocation through the gut wall
Enterome believes that sibofimloc has the potential to treat patients with various subsets of Inflammatory Bowel Disease (IBD), including Crohn’s disease, as well as in different therapeutic settings, such as patients with chronic active disease or requiring a maintenance therapy to maintain remission after surgery or other active therapy.
Sibofimloc is advancing through a Phase 2 clinical trial in post operation Crohn’s disease, under a co-development and co-commercialization partnership with Takeda Pharmaceuticals.